- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02344420
Clinical Investigation on Differences in the Magnitude of CRT Response in WOmen Versus MEN (BIOWOMEN)
Study to Compare the Cardiac Resynchronization Therapy (CRT) Response Rate in a Heart Failure (HF) Population With an Equal Distribution of Men and Women
Study Overview
Status
Conditions
Detailed Description
Prospective, non-randomized, international, open, multicenter study. Patients that comply with the inclusion and exclusion criteria will be implanted with a BIOTRONIK CRT system.
The primary objective is to study the magnitude of CRT response measured as function of increase in Left Ventricular Ejection Fraction (LVEF) in order to demonstrate a superior CRT response in women.
The Secondary main objectives are:
- To study changes in major clinical variables during a 12M FU period in men and women
- To study how Left Ventricular End Diastolic Volume (LVEDV) and Left Ventricular End Systolic Volume (LVESV) change in men and women with CRT response
- To study CRT responders and value if there are significant gender differences at baseline with regards of presence of inter/intra ventricular dyssynchrony, HF etiology (ischemic versus non-ischemic cardiomyopathy), QRS morphology (LBBB vs. RBBB) and QRSd
- Observational assessment of how key baseline clinical variables are related to the patient's CRT response, to create a possible "gender specific" response model.
- Study the relationship between QRSd (amount of dyssynchrony) and CRT response in men and women
There are no study specific requirements for the implantation procedure of the CRT device; implantation will be performed according to the routine hospital's practice.
In order to obtain an equal distribution of males and females in the study population enrolled by the site, all the inclusions should be performed consecutively (based on the normal hospital flow of CRT candidates), but the difference in the enrolment rate by gender should not exceed > 2 by site at any time during the enrolment phase.
The study flowchart consists of a baseline assessment, implantation/pre-hospital discharge, 2 month Follow Up (FU), 6 month FU, 12 month FU, and final study.
Special assessments as echocardiography (echo), 6 minute walk test and Quality of Life test (QOL) will be performed at baseline, after 6 months and at one year follow-up.
12-lead electrocardiogram (ECG) will only be performed at baseline. Device testing, (Serious) Adverse (Device) Events ((S)A(D)E), and changes in medication will be collected during all planned study FUs throughout the duration of the study. A device interrogation outside the scheduled study FU window needs to be reported as unscheduled FU.
The timing for scheduled FUs is at 2 month, 6 month and 12 month after implantation (and pre-hospital discharge) with a time window of ± 1 month.
All the echo images and ECGs will be saved and sent to the respective Core Labs.
The estimated sample size is 494 patients: 247 men and 247 women.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46026
- Hospital Clinico Universitario La Fe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for a "De Novo" implantation of a CRT device according to ESC Guidelines
- Understand the nature of the procedure
- Give written informed consent
Exclusion Criteria:
- CRT Device replacements
- CRT upgrades
- Permanent / Persistent Atrial Fibrillation
- Age< 18 years
- Pregnant and breastfeeding women
- Subjects with irreversible brain damage from pre existing cerebral disease
- Subjects with acutely de compensated heart failure
- NYHA Class IV Heart Failure
- Heart transplantation six months prior to the enrolment or expected within next 3 months.
- Cardiac surgery 3 months prior to the enrolment or planned within next 3 months.
- Have a life expectancy of less than 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single Arm
As it is not a randomize trial there is only one study arm.
Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
|
The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study. Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization.
MLHF will be obtained at baseline, 6 and 12 month FU.
The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life.
Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
The test will be performed at baseline, 6 and 12 month FU.
The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left Ventricular Ejection Fraction (LVEF) changes at 12 month Follow Up (FU)
Time Frame: Baseline, 6 and 12 month
|
To study the magnitude of Cardiac Resynchronization Therapy (CRT) response in women measured as a function of improvement in LVEF at 12moth FU in order to demonstrate that CRT response in women is better than men.
|
Baseline, 6 and 12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left Ventricular End Diastolic Volume (LVEDV)
Time Frame: Baseline, 6 and 12 month
|
Reverse left ventricular remodelling is a promising surrogate measure of outcome after CRT.
Left ventricular diastolic volumes will be compared between men and women to see if there are differences.
|
Baseline, 6 and 12 month
|
Left Ventricular End Systolic Volume (LVESV)
Time Frame: Baseline, 6 and 12 month
|
Reverse left ventricular remodelling is a promising surrogate measure of outcome after CRT.
Left ventricular systolic volumes will be compared between men and women to see if there are differences.
|
Baseline, 6 and 12 month
|
NYHA class
Time Frame: Baseline, 6 and 12 month Follow Up
|
Clinical variable collect to evaluate patients heart failure
|
Baseline, 6 and 12 month Follow Up
|
Quality Of Life test (QOL score)
Time Frame: Baseline, 6 and 12 month Follow Up
|
Test perform by the patient to measure the perception of how is the heart failure and it´s treatment affected in their daily routine.
|
Baseline, 6 and 12 month Follow Up
|
Patient's global self-assessment score
Time Frame: 2, 6 and 12 month Follow Up
|
Questionnaire perform by the patient to evaluate how is the heart failure.
|
2, 6 and 12 month Follow Up
|
6 minute walk test
Time Frame: Baseline, 6 and 12 month Follow Up
|
Test perform by the patient to evaluate how is the heart failure.
|
Baseline, 6 and 12 month Follow Up
|
12 lead electrocardiogram (ECG)
Time Frame: Baseline
|
A standard 12-lead ECG at 25 mm speed obtained.
QRS with will be measured to relate with CRT response.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria Jose MS Sancho-Tello, Physician, Hospital Universitario La Fe de Valencia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIOTRONIK-CR017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Echocardiography
-
Kang YanRecruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
-
Assiut UniversityUnknownCORONARY ARTERY BYPASSEgypt
-
Assiut UniversityNot yet recruiting
-
Weill Medical College of Cornell UniversityWithdrawn3D Transesophageal and Transthoracic EchocardiogramUnited States
-
Assiut UniversityUnknownMyocardial Infarction | Left Ventricular Dysfunction | Echocardiography 2DEgypt
-
Milton S. Hershey Medical CenterCompletedEchocardiography, Transesophageal | Ventricular Function, RightUnited States
-
London North West Healthcare NHS TrustRecruitingCoronary Artery DiseaseUnited Kingdom
-
Papworth Hospital NHS Foundation TrustUnknownChronic Thromboembolic Pulmonary Hypertension
-
Assiut UniversityNot yet recruiting